421 patents
Utility
Substituted heterocyclic compounds
9 Jan 24
Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Zili Xiao
Filed: 13 May 22
Utility
Naphthyridinone compounds useful as T cell activators
9 Jan 24
Louis S. Chupak, Min Ding, Robert G. Gentles, Yazhong Huang, Scott W. Martin, Ivar M. Mcdonald, Stephen E. Mercer, Richard E. Olson, Upender Velaparthi, Michael Wichroski, Xiaofan Zheng
Filed: 26 Jun 19
Utility
Oligomeric particle reagents and methods of use thereof
9 Jan 24
Provided herein are oligomeric reagents, including oligomeric reagents of streptavidin or a streptavidin mutein, compositions thereof, and methods for manufacturing oligomeric reagents, including methods for reliably manufacturing oligomeric particle reagents of a desired size.
Thomas Schmidt, Christian Stemberger, Tom Kowski, Ken Prentice
Filed: 27 Apr 18
Utility
Fibronectin based scaffold domain proteins that bind PCSK9
2 Jan 24
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9.
Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
Filed: 16 Feb 21
Utility
System for verifying accuracy of serially-connected drug modules in a combinatorial drug delivery device
19 Dec 23
In one aspect, a system is provided of verifying the accuracy of a plurality of serially-connected drug modules of a combinatorial drug delivery device, each of the drug modules including a drug reservoir, the system including: a machine-readable code located on each of the drug modules; application software configured to generate an activation code based on the machine-readable codes and the sequence of the machine-readable codes; a flow controller on the drug delivery device which is selectively actuatable to a use state to permit flow of drug from the drug delivery device; and, a control unit on the drug delivery device having a computing processing unit configured to compare the activation code with an authentication code, and, wherein, if the authentication code matches the activation code, the computing processing unit causes actuation of the flow controller to permit flow of the drug from the drug delivery device.
Martin John McLoughlin
Filed: 21 Oct 20
Utility
Cation exchange resins
12 Dec 23
In some embodiments, the present invention provides a method of purifying a protein of interest with a reduced level of aggregation formation in cation exchange (CEX) chromatography, comprising: (a) providing a mixture comprising the protein of interest and one or more contaminants; (b) loading the mixture onto a CEX resin coupled with arginine; and (c) eluting the protein of interest from the resin, thereby purifying the protein of interest with a reduced level of aggregation formation in CEX chromatography.
Zhengjian Li, Xuankuo Xu, Chao Huang, Zhiqiang Chen
Filed: 10 Feb 21
Utility
Substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
28 Nov 23
Improved methods and intermediates thereof for preparing substituted 4-amino-1H-imidazo[4,5-c]quinoline compounds are described.
Sha Lou, Adrian Ortiz, Christopher Robert Jamison, Eric M. Simmons
Filed: 22 Nov 22
Utility
NLRP3 modulators
28 Nov 23
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human).
Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
Filed: 6 May 21
Utility
Antibodies to alpha-synuclein and uses thereof
28 Nov 23
Disclosed herein are anti-α-synuclein antibodies which preferentially bind to oligomeric α-synuclein over monomeric α-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
Michael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
Filed: 19 Jan 21
Utility
4-azaindole compounds
21 Nov 23
Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Trevor C. Sherwood, Brian K. Whiteley, John L. Gilmore, Sreekantha Ratna Kumar, Laxman Pasunoori, Pitani Veera Venkata Srinivas, Srinivasan Kunchithapatham Duraisamy, Subramanya Hegde, Rushith Kumar Anumula
Filed: 30 Apr 21
Utility
Fibronectin based scaffold domain proteins that bind to myostatin
14 Nov 23
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin.
Sharon Cload, Linda Engle, Dasa Lipovsek, Malavi Madireddi, Ginger Chao Rakestraw, Joanna Swain, Wenjun Zhao, Hui Wei, Aaron P. Yamniuk, Vidhyashankar Ramamurthy, Alexander T. Kozhich, Martin J. Corbett, Stanley Richard Krystek, Jr.
Filed: 14 Feb 19
Utility
Bi-specific antigen-binding polypeptides
14 Nov 23
The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity.
Yan Chen, Richard W. Wagner, Keming Zhang, Pascale Richalet
Filed: 22 Jan 19
Utility
Imaging methods using 18F-radiolabeled biologics
7 Nov 23
The invention relates to water soluble 18F-prosthetic groups and the synthesis and use of 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
David Donnelly, David K. Leung
Filed: 10 Nov 22
Utility
Treatment of LAG-3 positive tumors
7 Nov 23
The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody.
James Novotny, Jr., Nils Lonberg, Cyrus Hedvat, Raphael Clynes, Darren Locke, John P. Cogswell, Jeffrey Jackson, Christopher Harbison, Robin Edwards
Filed: 30 May 18
Utility
Combinatorial drug delivery device
31 Oct 23
In one aspect, a combinatorial drug delivery device is provided for delivering a predetermined selection of drug components.
Martin John McLoughlin, Chester Larrow, Mariano Mumpower
Filed: 26 Oct 22
Utility
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
31 Oct 23
Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR).
Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
Filed: 25 Oct 19
Utility
Antagonistic CD40 monoclonal antibodies and uses thereof
24 Oct 23
The disclosure provides for antibodies that bind CD40, including a humanized antibody.
Aaron Yamniuk, Mary Struthers, Stanley R. Krystek, Jr., Akbar Nayeem, Ginger Rakestraw
Filed: 11 Feb 22
Utility
Sulfone pyridine alkyl amide-substituted heteroaryl compounds
17 Oct 23
Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
Filed: 28 Apr 21
Utility
TIM-3 antagonists for the treatment and diagnosis of cancers
17 Oct 23
Provided herein are methods for treating a subject afflicted with a cancer, comprising administering to the subject a TIM3 agonist (e.g., an anti-TIM3 antibody), alone or in conjunction with another immune checkpoint inhibitor (e.g., a PD-1 antagonist), wherein the subject is identified as having a high frequency of TIM3 positive cells (e.g., on the tumor infiltrating inflammatory cells) or soluble TIM3 in peripheral blood.
Anke Klippel, Laurence Celine Menard
Filed: 28 Aug 18
Utility
Classifying pharmacovigilance documents using image analysis
17 Oct 23
Provided herein are system, apparatus, device, method, and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for classifying a document using image analysis.
Sameen Mayur Desai
Filed: 11 Jun 21